#ALS AWARENESS #LouGehrigsDisease #PARKINSONS

This clinical trial will test the safety of increasing doses of stem cells injected into the spinal cord of patients with ALS.  There will be 15 - 18 patients in the study, separated into 5 dosing groups, A-E, with 3 patients in each group.  The first 4 groups will receive injections into the cervical spinal cord in the neck, into the region that controls the breathing muscles.  The subjects will receive either 5 (group A) or 10 (group B-E) injections on both sides of the spinal cord, for a total of either 10 or 20 injections.  The number of cells will increase with each dosing group from 2 million to 8 million cells injected.  Group E subjects will undergo two surgeries, first injections into the lumbar cord (lower spine) followed several weeks later by injections into the cervical spinal cord. 

Eligible participants must all be able to....................

Researchers at the University of Wisconsin-Madison have accomplished a notable feat in stem cell research that could lead to new models for drug screening and discovery--they have transformed human embryonic stem cells into nerve cells that helped mice regain the ability to learn and remember.

In what the UW scientists believe is the first study of its kind, a.............

BrainStorm Cell Therapeutics (otcqb:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the European Commission has granted Orphan Drug Designation for NurOwn(TM), the Company's stem cell therapy consisting of autologous bone marrow-derived mesenchymal stromal cells secreting neurotrophic factors, for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease. NurOwn received Orphan Drug Designation from the............

Neuralstem, Inc. (NYSE MKT: CUR) announced that Jonathon Glass, MD, Director of the Emory ALS Center, presented new data from the Phase I trial of Neuralstem's human spinal cord stem cells, NSI-566, in amyotrophic lateral sclerosis...